BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models.
Jiang B, Zhang T, Deng M, Jin W, Hong Y, Chen X, Chen X, Wang J, Hou H, Gao Y, Gong W, Wang X, Li H, Zhou X, Feng Y, Zhang B, Jiang B, Lu X, Zhang L, Li Y, Song W, Sun H, Wang Z, Song X, Shen Z, Liu X, Li K, Wang L, Liu Y.
Jiang B, et al. Among authors: wang x, wang l, wang j, wang z.
Front Med. 2023 Dec;17(6):1170-1185. doi: 10.1007/s11684-023-0996-8. Epub 2023 Sep 25.
Front Med. 2023.
PMID: 37747585